The latest verified reporting and analysis across science.
ESA’s first major Euclid release spans 1,900 square degrees and includes spectra for more than 160 million sources plus about 15,000 strong-lens candidates. It is an unprecedented research foundation, not yet the mission’s promised measurement of dark energy and dark matter.
Read story
The Unified Patent Court has found Pfizer and BioNTech’s Comirnaty vaccine infringes a mostly valid GSK patent and awarded interim damages. Its cross-border injunction cannot take effect until the ruling is final and a further three-month licensing window expires.
Read story
Risto-cel reached its prespecified efficacy and safety endpoints in Beam Therapeutics’ BEACON study, supporting a planned FDA filing. But the company’s topline announcement omits the endpoint numerator, itemized safety results and durability data needed to judge the therapy against existing gene-edited treatments.
Read story
A triaxially woven polymer network separated benzene from cyclohexane and could be regenerated for reuse. The Nature study establishes an unusual molecular architecture and promising selectivity, but it does not yet quantify process energy, economics, throughput or commercial durability.
Read story
Shanghai Jiao Tong University’s AI-native biology laboratory coordinated more than 20 instrument types across DNA synthesis, storage and mutation-detection demonstrations. Its real advance is orchestration, not a fully unmanned lab or a validated clinical test.
Read story
GSK and Moderna have settled U.S. and European disputes over COVID-19 and RSV vaccine technology through infectious-disease patent cross-licenses that require no payments. The agreement removes litigation risk without establishing whose patents were valid or infringed.
Read story
ExoMars measurements repeatedly place trace hydrogen chloride above fissures near Alba Mons during an unusual season. The pattern strengthens the case for recent or continuing activity below Mars, but no magma, eruption or hydrothermal system has been directly observed.
Read story
Ifezuntirgene inilparvovec could become the first treatment intended to alter Huntington’s disease progression. Its May 2027 review deadline is a milestone, not an endorsement: the application relies on a small Phase I/II program and external controls, while four-year results missed statistical significance on the primary measure.
Read story
Project Suncatcher has completed an end-to-end inference test in orbit, returning a short response as the spacecraft passed Svalbard. The milestone proves a data-centre-class accelerator can execute a model in space, but not that orbital AI infrastructure is yet practical.
Read story